<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903119</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20-MEL-11-PMC</org_study_id>
    <nct_id>NCT04903119</nct_id>
  </id_info>
  <brief_title>Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma</brief_title>
  <official_title>A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peng Wang, MD PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose&#xD;
      dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma&#xD;
      carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal is&#xD;
      to assess the toxicity and tolerability and determine the maximum tolerated dose&#xD;
      (MTD)/recommended phase 2 dose (RP2D) of the combination of nilotinib with dabrafenib and&#xD;
      trametinib. Additionally, this study will assess pharmacokinetic parameters of dabrafenib and&#xD;
      nilotinib when used in combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1 dose-escalation study of nilotinib in combination with a fixed-dose of&#xD;
      dabrafenib and trametinib. The first week, patients will be treated with dabrafenib (150mg,&#xD;
      twice daily) and trametinib (2mg, once daily). After 7 days, when both drugs have achieved&#xD;
      steady-state levels and there is maximal induction of CYP3A4, nilotinib will be added, and&#xD;
      all three drugs dosed concurrently for the rest of the study. Plasma pharmacokinetic (PKs)&#xD;
      samples for dabrafenib and nilotinib will be obtained at baseline, weekly for the first four&#xD;
      weeks, and at regular study visits for the duration of the trial. Tissue core biopsies and&#xD;
      correlative plasma samples will be obtained at baseline, and 2 weeks after the start of&#xD;
      nilotinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Experiencing Dose Limiting Toxicities</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of patients who experienced dose-limiting toxicities associated with Nilotinib as defined by the study protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-Adjusted Steady State Concentration of Dabrafenib</measure>
    <time_frame>15 days</time_frame>
    <description>The dose-adjusted steady state concentrations (Css) of dabrafenib will be calculated on day 8 (dabrafenib alone) compared to day 15 (dabrafenib + nilotinib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nilotinib Concentration</measure>
    <time_frame>1 month</time_frame>
    <description>Plasma concentrations of Nilotinib will be measured on day 8 (pre-Nilotinib) and day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of overall response will be determined by the time measurement criteria are met for complete response (CR) or partial response (PR) - whichever is first recorded - until the first date that recurrent or progressive disease is objectively documented.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>BRAF Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive 100mg Nilotinib PO BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive 200mg Nilotinib PO BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive 300mg Nilotinib PO BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive 400mg Nilotinib PO BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib 100mg</intervention_name>
    <description>Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.</description>
    <arm_group_label>Level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib 200mg</intervention_name>
    <description>Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.</description>
    <arm_group_label>Level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib 300mg</intervention_name>
    <description>Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.</description>
    <arm_group_label>Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib 400mg</intervention_name>
    <description>Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.</description>
    <arm_group_label>Level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.</description>
    <arm_group_label>Level 1</arm_group_label>
    <arm_group_label>Level 2</arm_group_label>
    <arm_group_label>Level 3</arm_group_label>
    <arm_group_label>Level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.</description>
    <arm_group_label>Level 1</arm_group_label>
    <arm_group_label>Level 2</arm_group_label>
    <arm_group_label>Level 3</arm_group_label>
    <arm_group_label>Level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed metastatic or unresectable melanoma&#xD;
&#xD;
          -  Patients must have a BRAF V600 mutation&#xD;
&#xD;
          -  Patients must have failed any BRAFi/MEKi regimen to qualify for the trial&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ECOG performance status ≤ 1&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus (HIV) on effective anti-retroviral&#xD;
             therapy with undetectable viral load within 6 months are eligible&#xD;
&#xD;
          -  HBV viral load must be undetectable on suppressive therapy, if indicated.&#xD;
&#xD;
          -  Patients must have an undetectable HCV viral load.&#xD;
&#xD;
          -  Patients with treated brain metastases are eligible if follow-up brain imaging 4 weeks&#xD;
             or longer after central nervous system (CNS)-directed therapy shows no evidence of&#xD;
             progression.&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial.&#xD;
&#xD;
          -  Patients with known history or current symptoms of cardiac disease, or history of&#xD;
             treatment with cardiotoxic agents, should have a clinical risk assessment&#xD;
&#xD;
          -  women of childbearing potential and men must agree to use adequate contraception&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic hypokalemia or chronic hypomagnesemia&#xD;
&#xD;
          -  Patients with long QT syndrome or baseline QTc (Fridericia) &gt;470 msec in males and&#xD;
             &gt;480 msec in females&#xD;
&#xD;
          -  Patients who are receiving any other investigational therapies that could affect the&#xD;
             primary or secondary outcomes of this study&#xD;
&#xD;
          -  Untreated brain metastases&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to nilotinib, dabrafenib, and trametinib.&#xD;
&#xD;
          -  Patients receiving any medications or substances that are strong CYP3A or CYP2C8&#xD;
             inhibitors or substances that are strong CYP3A inducers&#xD;
&#xD;
          -  Use of Proton pump inhibitors concurrent with nilotinib&#xD;
&#xD;
          -  Use of drugs or substances known to prolong QT interval is prohibited with Nilotinib&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness.&#xD;
&#xD;
          -  Patients with psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Other prior malignancy active within 2 years, except for localized prostate cancer,&#xD;
             cervical carcinoma in situ, non-melanoma carcinoma of the skin, stage 1 differentiated&#xD;
             thyroid cancer or ductal carcinoma in situ of the breast that has/have undergone&#xD;
             curative surgery or radiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne Taul, RN</last_name>
    <phone>859-323-7628</phone>
    <email>Yvonne.Taul@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Taul, RN</last_name>
      <phone>859-323-7628</phone>
      <email>yvonne.taul@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Peng Wang, MD PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>dose escalation</keyword>
  <keyword>nilotinib</keyword>
  <keyword>dabrafenib</keyword>
  <keyword>trametinib</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>CYP3A4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

